1 BIOTRON LIMITED (ASX:BIT) Mid-Clinical Stage Antiviral Drug Development Company Investor Update 20 August 2015 Dr Michelle Miller Managing Director
2 Forward Looking Statements This presentation may contain forward looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN ) and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as should, expects, anticipates, estimates, believes or similar expressions, as they relate to Biotron Limited, are intended to identify forward looking statements. By their nature, forward looking statements involve risk and uncertainty because they reflect Biotron s current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.
3 Financial Information Key Financial Metrics 12 Month Share Price Performance Ticker Code ASX: BIT Share Price (19 Aug 2015) A $0.10 Ticker Code ASX: BIT Market cap A $31.3 million Share Price (15 Sept 2014) A $ Month Trading Range A $ Shares Outstanding 313 million Market cap A $26.3 million Options (BITO) 50.7 million $0.12 expiry 30/09/16 12 Month Trading Range A $ Cash Position (06/2015) A $6.5 million Shares Outstanding 228 million Board Michael Hoy Non-executive Chairman Michelle Miller Managing Director Susan Pond Non-executive Director Rob Thomas Non-executive Director Denis Wade Non-executive Director Cash Position (06/14) A $1.76mn Slide 1
4 BIT225 Snapshot - Prepared based on above after the August Board meeting - First in class drug and new drug target for treatment of HIV and Hepatitis C virus (HCV) - Guided the wording of the prospectus draft and the use of proceeds - Seven clinical trials completed; another is fully recruited - While capital requirements are determined based on proposed plan, the final schedule - Demonstrated clinical activity against HCV G1 and G3 of work will be largely dictated by available capital - Independently shown to have HCV pan-genotype activity in vitro - Efficiently inhibits HIV replication in monocyte/macrophage reservoir cells in vitro and in vivo - Patent position over compound and its uses - Compound is relatively easy to make and formulate; very stable at room temperature important for supply chains - Significantly undervalued compared to other HCV drugs = potential for considerable upside Slide 2
5 Significant Progress During Last 12 Months ACTIVITY Phase 2 HIV/HCV co-infected trial STATUS/OUTCOME 100% SVR12 data reported for HIV/HCV G3 Phase 2a HIV trial Phase 2, three-month dosing HCV G1 & G3 trial Development of BIT225 capsules Patent position strengthened $8 million raised Impact on immune activation reported Fully recruited; SVR12 G3 3Q15; SVR12 G1 1Q16 Improves delivery of BIT225, in a user friendly format suitable for larger scale trials Key patents for BIT225 and other compounds issued in the USA and other jurisdictions July 15 Placement plus SPP raised $4 million; Nov 14 - fully underwritten rights issue closed over-subscribed with no shortfall raising $4 million Slide 3
6 Biotron s Core Technology & Pipeline Designed library of compounds to target viroporins: >250 compounds designed and synthesised Compounds screened in proprietary assay set up for each virus target e.g. HIV Vpu; HCV p7; Influenza M2; Dengue M; Coronavirus E. HCV BIT225 Leads PIPELINE PRE- CLIN PH 1 PH 2 PH 3 VIROPORINS - New class of viral proteins - Key roles in production and release of infectious virus Hits tested against virus in cell cultures Lead optimisation and selection DENGUE Several compounds with promising antiviral activity HIV/HCV BIT225 HIV BIT225 Next gen HCV BIT314 Dengue 10, (2012) BIT314 (HCV) BIT225 (HIV and HCV) Slide 4
7 BIT225 - Proven Clinical Track Record - Over 200 patients and healthy volunteers dosed with BIT225 to date - Positive data recorded in all trials - HCV G1 (BIT ) 100% receiving 400mg (28 days in combination with 48 weeks IFN/RBV) were virus-free at 48 weeks - Co-infected HIV/HCV GT3 (BIT ) 100% completing course of 300mg (28 days in combination with 48 weeks IFN/RBV) were HCV-free 12 weeks post-treatment (SVR12) i.e. cured of HCV infection - BIT225 increases the rate at which HCV is cleared Slide 5
8 Large and Growing Global Market for Hepatitis C Forecast to grow to over $19bn by million infected worldwide (3% world population) ~3 to 5 million in US & 30 million in China New drugs have demonstrated significant pricing power Gilead s Sovaldi (Sofosbuvir) at US$84,000 for a 12 week course Best performing first year sales: ~US$10 billion Recent new HCV drug combinations not optimal Lengthy treatment 12 weeks or more Not pan-genotypic BIT225 is pan-genotypic in vitro Not as effective against HCV G3 BIT225 has good activity against HCV G3 More treatment failures than anticipated need for new classes of drugs like BIT225 Partnering still active J&J partnered Achillion in US$1.1 bn deal in May 15; Merck bought Idenix for US$3.8 bn in June 14 Slide 6
9 BIT : Phase 2 HCV Three-Month Dosing Trial n=20 n=20 Placebo + IFN/RBV (HCV Genotype 1 or 3) BIT mg BID + IFN/RBV HCV Genotype 1 IFN/RBV (G3 to week 24; G1 to week 48) IFN/RBV n=20 BIT mg BID + IFN/RBV HCV Genotype 3 IFN/RBV Week 12 Design: - Randomised, placebo-controlled, double-blind trial (n=60) - Treatment naïve, HCV gen 1 and 3-3 months dosing with BIT225 in combination with IFN/RBV - Using new capsule formulation fold higher blood levels than previous formulation - Fully recruited - SVR12 for G3 due 3Q15; SVR12 for G1 due 1Q *SVR12 FOR G3 Aims: 48 - Demonstrate safety of BIT225 with 3 months dosing - Extend HCV gen 3 efficacy data - Provide key data to assist with determining future dosing with BIT225 capsules - Generate safety data to support US FDA IND filing for combination trial with other HCV direct-acting antivirals (DAAs) 60 *SVR12 FOR G1 Slide 7
10 HIV Towards a Cure Infection rates in Australia are at 20 year high Over 1.1 million people living with HIV in the USA, with 1 in 6 unaware of diagnosis US$11.9 bn sales in US, Europe and Japan in 2013; expected to grow to US$16.8 bn by 2020 HIV patients need to stay on antiretroviral drugs (ART) to keep virus levels under control New mode of actions drugs are needed to eradicate or cure HIV infection Slide 8
11 BIT225 inhibits assembly and budding of new virus Phase 2a trial (004) showed that BIT225 can reduce HIV levels in macrophage cells in vivo, paralleling in vitro studies Potential benefits on immune aging and HIV-associated dementia Potential for use in future virus eradication treatment Progressing to pivotal Phase 2 HIV trial A BIT225 Targets HIV in Reservoir Cells B In vitro Effect on HIV Replication d14 infection & d21 BIT225 addition Placebo 100 +BIT (A) Untreated Controls (B) BIT225 treated cells HIV-1 Time (days) Slide 9
12 Dengue Virus Program 2.5 billion people (40% world population) live in areas at risk of Dengue ~100 million people infected yearly A leading cause of illness and death in tropics and subtropics Transmission is by mosquito; most prevention programs target the vector No approved Dengue-specific therapeutic Vaccine trials have had disappointing results Biotron is targeting Dengue M protein Similar target to HIV/Vpu and HCV/p7 Several compounds with promising activity at early stage of development Slide 10
13 Investment Proposition HCV and HIV are high growth, multi-billion dollar markets Significant treatment gaps remain BIT225 is a novel approach with demonstrated promising efficacy in Phase 2a/2 clinical trials Represents a new class of direct-acting HCV drugs Potential to fill significant HCV treatment gaps HCV Genotype 3 HIV/HCV co-infected patients Cirrhotic patients & treatment failures Potential to eradicate important HIV reservoirs, plus may impact on HIV-associated dementia Flexibility to combine with any other HCV and HIV drug combinations Significantly undervalued in comparison with other HCV companies Slide 11
14 Outlook for 2015/16 Complete BIT HCV trial currently in progress SVR12 for G3 due 3Q15; SVR12 for G1 due 1Q16 Investigational New Drug application (IND) Engaged with FDA - pre-ind consultation HCV combination trial with DAA File HCV IND application late 2015 Currently completing studies required by FDA Progress protocol and regulatory documentation for key Phase 2 HIV trial Expand earlier stage drug programs e.g. Dengue virus when funding available Continue commercialisation activities aimed at attracting partners Continue to promote company to local and international investment community Slide 12
Interim report as of March 31, 2015 MOLOGEN AG interim report as of March 31, 2015 Key data 2 Highlights Slight decline in research and development expenses EBIT improved accordingly Ongoing recruitment
BioMS Medical Corp Management Discussion And Analysis of Financial Condition And Results of Operations May 15, 2008 For the three months ended Management s Discussion and Analysis (MD&A) of Financial Condition
Understanding the Clinical Research Process and Principles of Clinical Research Participant Guide Name INTRODUCTION... 1 What Is AIDS?...1 What Is the History of AIDS?...2 What Are the Division of AIDS
Annual report and accounts for the together Contents 1 Chairman s review 2 Chief Executive Officer s review 4 Financial review 20 Board of Directors 22 Directors report 24 Nomination Committee report 25
2009 Annual Report PRE-CLINICAL AND CLINICAL PRODUCT PIPELINE AS OF MARCH 2, 2010 Development Phase Product Disease Indications Pre-Clinical I I/II II III Ofatumumab 17 studies Partner: GSK Chronic lymphocytic
9-MoNth financial report 2013 UCB acquires rights to an antibody programme for non-oncology indications Cooperation and licence agreement for ADC signed with Roche Nuclea acquires WILEX Inc. and will develop
Bringing innovation to global health Crucell 2010 www.crucell.com Contents Our mission Crucell s mission is to protect human lives from infectious diseases by bringing meaningful innovation to global health.
ANNUAL REPORT 2006 AND FORM 20-F INFORMATION CONTENTS 2006 IN BRIEF 1 CHAIRMAN S STATEMENT 2 CHIEF EXECUTIVE OFFICER S REVIEW 3 FINANCIAL HIGHLIGHTS 6 DIRECTORS REPORT Business review 8 > Business environment
MANAGEMENT S DISCUSSION AND ANALYSIS Dated: July 9, This Management's Discussion and Analysis ("MD&A") for the three months ended (second quarter of fiscal ) provides detailed information on the operating
Tesla Motors, Inc. Fourth Quarter & Full Year 2013 Shareholder Letter Record 6,892 Model S vehicles sold and delivered in Q4 World s highest Consumer Reports customer satisfaction score of 99/100 Q4 auto
As filed with the Securities and Exchange Commission on June 13, 2007 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) Registration statement pursuant to Section
QUARTERLY REPORT Interim Report and Quarterly Management Report by 31 March 2008 CONTENTS QUARTERLY REPORT BY 31 MARCH 2008 Contents The Company General information 04 Key figures 05 Shareholders letter
the true value of any business is in its people annual report 2008 contents profile 3 our services 4 our mission, global presence and culture 5 our core values, unit model and strategic approach 6 profile
Biologics and biosimilars An overview Contents An introduction to biotechnology... 3 A brief history of medicine development... 4 What are biologic medicines?... 5 How are biologic medicines developed?...
adsad Action Plan for the Prevention, Care, & Treatment of Viral Hepatitis Updated 2014-2016 This digital version of the 2014-2016 Action Plan for the Prevention, Care, and Treatment of Viral Hepatitis--
Evotec A deal to dream for and key data due soon Sanofi deal, Q115 results Pharma & biotech The exceptional deal with Sanofi for its Toulouse facility at no cost provides Evotec with a platform to accelerate
Boehringer Ingelheim Annual Press Conference 2015 Wednesday, 22 April 2015 Boehringer Ingelheim Center, Ingelheim, Germany The remarks of Andreas Barner Hubertus von Baumbach Members of the Board of Managing
1 PHARMING ANNUAL REPORT 2013 2013 highlights Operational Ruconest continues roll- out across Europe. o Roll- out begun to accelerate and in- market sales started trending upwards during the last months
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL TRIALS E8 Current
PROSPECTUS The Offer contained in this Prospectus is an invitation by LifeHealthcare Group Limited ACN 166 525 186 to apply for fully paid ordinary shares in the Company. Lead Manager Important Information
ASSET MANAGEMENT STRATEGY Version 3 - Final Adopted 19 February 2013 NAMS.PLUS Burnie City Council Asset Strategy Document Control Document Control NAMS.PLUS Asset www.ipwea.org.au/namsplus Document ID:
BIONOMICS IS A LEADING INTERNATIONAL DRUG DISCOVERY AND DEVELOPMENT COMPANY BREAST CANCER BEFORE BNC105 TREATMENT BREAST CANCER AFTER BNC105 TREATMENT LIFE TRANSFORMING TREATMENTS FOR CANCER AND CNS DISORDERS
Oramed Pharmaceuticals LifeSci Investment Abstract Oramed Pharmaceuticals (NASDAQ: ORMP) is a clinicalstage pharmaceutical company specializing in the oral delivery of proteins for large disease indications.
Initiation Note September 16, 2014 Evotec AG (EVT.F) Furnished by MERRIMAN CAPITAL Financial Entrepreneur Platform Initiation: Capturing Value as Evotec Adds Pipeline Generation to Drug Discovery Engine.
HHS Pandemic Influenza Plan U.S. Department of Health and Human Services November 2005 HHS Pandemic Influenza Plan U.S. Department of Health and Human Services November 2005 HHS Pandemic Influenza Plan